Answers are grounded in this paper and cite their sources.
Acute leukaemia of ambiguous lineage (ALAL) is a rare and heterogeneous leukaemia with unsatisfactory outcomes from conventional chemotherapy. Venetoclax (VEN) has shown potential efficacy in ALAL. Our pilot study demonstrated that VEN combined with multi-frequency decitabine (DEC) was safe and effective in elderly acute myeloid leukaemia (AML) patients. We therefore designed VDVD regimen (VEN, multi-frequency DEC, vincristine, dexamethasone) as induction therapy for de novo ALAL. VDVD comprised VEN (100 mg d1, 200 mg d2, 400 mg d3-11), DEC (20 mg/m² every 8 hours d4-6), vincristine (2 mg/d d1,8), and dexamethasone (10 mg/m² d1-4,8–11). Dasatinib was added for BCR::ABL1-positive patients. Hematopoietic stem cell transplantation (HSCT) was recommended upon achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). The primary endpoint was overall response rate (ORR); secondary endpoints included overall survival (OS), event-free survival (EFS) and disease-free survival (DFS). This multicenter retrospective study included 19 patients with de novo ALAL (median age 58 years, range 15–71) from 8 hospitals in China, all of whom were treated with the VDVD regimen.After one induction cycle, ORR(CR + morphologic leukaemia-free state, MLFS + partial remission, PR) was 94.73% (18/19), with CR rate of 84.21% (16/19). No induction deaths occurred. At median follow-up of 11 months (range 2–36), 3 (15.79%) patients underwent HSCT. Median OS was 11 months (range 2–36), median EFS and DFS were both 9.5 months (range 1–31). In conclusion, the VDVD regimen demonstrates promising efficacy and a manageable safety profile as induction therapy for de novo ALAL.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: